CPG
ALNY icon

Cornerstone Planning Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cornerstone Planning Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.9K Sell
97
-3
-3% -$905 ﹤0.01% 587
2026
Q1 		$30.1K Buy
100
+5
+5% +$1.7K ﹤0.01% 542
2025
Q4 		$33.2K Sell
95
-397
-81% -$176K 0.01% 443
2025
Q3 		$56.2K Buy
492
+450
+1,071% +$183K 0.01% 314
2025
Q2 		$17.6K Buy
42
+8
+24% +$2.21K ﹤0.01% 446
2025
Q1 		$8.23K Buy
34
+11
+48% +$2.83K ﹤0.01% 620
2024
Q4 		$6.37K Hold
23
– – ﹤0.01% 530
2024
Q3 		$6.55K Buy
23
+10
+77% +$2.6K ﹤0.01% 511
2024
Q2 		$3.44K Buy
+13
New +$2.05K ﹤0.01% 650
2024
Q1 		– Sell
-1
Closed -$191 – 1109
2023
Q4 		$191 Hold
1
– – ﹤0.01% 865
2023
Q3 		$177 Buy
+1
New +$191 ﹤0.01% 1040

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cornerstone Planning Group's ALNY Position: Q2 2026 in Review

Cornerstone Planning Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 3% in Q2 2026, selling an estimated $905 and leaving 97 shares worth $25.9K. The position accounts for ﹤0.01% of the portfolio, ranked #587.

Cornerstone Planning Group first reported a position in ALNY in Q3 2023 and has held it in 11 quarters since. The position peaked at $56.2K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Cornerstone Planning Group held 97 shares of Alnylam Pharmaceuticals worth $25.9K as of Q2 2026.
  • Cornerstone Planning Group sold 3 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $905.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #587 holding.
  • Cornerstone Planning Group first reported a position in Alnylam Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Cornerstone Planning Group's Alnylam Pharmaceuticals position peaked at $56.2K in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.